Pavord ID, Bourdin A, Papi A, Domingo C, et al. Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of ICS dose. Allergy 2023 Jul 11. doi: 10.1111/all.15792.
PMID: 37431558